To assist you in the care of your patients, we would like to alert you to the recall of certain lots of Symjepi® (epinephrine) injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) prefilled, single-dose syringes to the consumer level on March 22, 2022.1 We recommend you review your medical records and contact all patients for whom you have prescribed this medication to warn them of the recall.
Symjepi is intended for immediate administration in patients who are at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. The drug manufacturer, Adamis Pharmaceuticals Corp., is voluntarily recalling this product due to the potential clogging of the needle, which prevents the dispensing of life-saving epinephrine.
Other lot numbers of Symjepi are unaffected and readily available.
Product name | NDC number | Lot number | Expiration date |
---|---|---|---|
Symjepi (epinephrine) injection | 21101Y | 11/30/2022 | |
0.15 mg (0.15 mg/0.3 mL) | 78670-131-02 | 21041W | 8/31/2022 |
0.3 mg (0.3 mg/0.3 mL) | 78670-130-02 | 21081W | 11/30/2022 |
21102W | 2/28/2023 |
Information for providers:1
- We have sent a letter to your Humana-covered patients who have had a claim for Symjepi and asked them to contact their physicians or healthcare providers if their medication is included in the recall and if they have experienced problems that may be related to using these drug products.
- For questions regarding this recall, please contact USWorldMeds at 888-900-8796, Monday – Friday, 8 a.m. – 4 p.m., Eastern time, or email questions to
medinfo@usworldmeds.com . - Patients may report adverse reactions or quality problems experienced with the use of this product to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail
or by fax.
- Online: Complete and submit the
report .- Select “Consumer/Patient (FDA Form 3500B).”
- Regular mail or fax: Download the
form .- Select “Form FDA 3500B – Voluntary Reporting for Consumers” and submit by mail to the address on the form or by fax to 800-FDA-0178 (332-0178).
- Online: Complete and submit the
Reference:
- “Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (Epinephrine) Injection for Potential Manufacturing Defect,” U.S. Food and Drug Administration, last accessed March 28, 2022,
www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/adamis-pharmaceuticals-corporation-issues-nationwide-voluntary-recall-symjepir-epinephrine-injection .
Pharmacy news
Drug recall notice for metformin Drug recall notice for Nature-Throid and WP Thyroid tablets Drug recall notice for Belviq, Belviq XR (lorcaserin) Drug recall notice for NP Thyroid tablets Drug recall notice for Taro Pharmaceuticals phenytoin oral suspension Drug recall notice for nizatidine Ongoing ranitidine recalls Drug recall notice for Natpara Formulary changes for generic Ventolin HFA Formulary changes for generic Zytiga Impact of ongoing angiotensin II receptor blocker drug recalls